Latest Patents And Intellectual Property News

Mount Ridley Mines has lodged a provisional patent for its SelectroTM hydrometallurgical leach technology, demonstrating superior recoveries of rare earths, scandium, and gallium compared to conventional methods. The company is advancing testwork and commercial discussions to capitalise on the innovation.

Temas Resources posted a CAD 2.63 million loss for H1 2026, driven by ramped-up exploration and RCL technology development, while securing $1.5 million in fresh funding and signing initial RCL licensing contracts.

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Zeotech Limited has locked in a $204 million binding offtake agreement for its kaolin products and successfully demonstrated its AusPozz™ low-carbon metakaolin in a large-scale concrete pour, signaling strong momentum in its commercialisation efforts.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.

Zoono Group Limited has announced a pro rata non-renounceable rights issue aiming to raise approximately $1.78 million at $0.035 per share. The capital raise will support shelf-life extension projects, repay related party debt, and bolster working capital.

Zoono Group Limited is raising nearly $1.8 million through a non-renounceable rights issue to fund its supermarket shelf-life extension project in Asia and reduce related party debt.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.